A new collaboration between NYU Langone Health and NYU Winthrop is providing Long Islanders with direct access to NYU Langone’s world-class team that treats advanced heart failure with transplants and implanted heart-assist devices. Heart transplant services are led by esteemed cardiothoracic surgeon Nader Moazami, MD, who joined NYU Langone last year from the Cleveland Clinic. Dr. Moazami, who has performed more than 300 heart transplants, adds to a highly skilled team already serving NYU Winthrop patients. Services on Long Island include pre-surgical evaluations of candidates for implanted heart-assist devices and heart transplants, with these new services especially important given that heart disease and stroke are among the top health concerns among Long Islanders.
Photo of team (l-r): Dr. Kevin Marzo, Chief of the Cardiology Division at NYU Winthrop joins with the NYU Langone team of Jennifer Pavone, Nurse Practitioner and Heart Transplant Program Manager; Dr. Nader Moazami, Surgical Director of Heart Transplantation and Mechanical Circulatory Support; and Dr. Alex Reyentovich, Medical Director of the Heart Transplant and Ventricular Assist Device Program.
The collaborative services are conducted in Mineola at 212 Jericho Turnpike, while the actual heart transplants or implantation of heart-assist devices, such as left ventricular heart assist devices (LVAD), are performed at NYU Langone in New York City. Helping to lead this collaborative team is also Alex Reyentovich, MD, Medical Director of the Heart Transplant and Ventricular Assist Device Program at NYU Langone Health. Dr. Reyentovich and his team of fellowship-trained heart failure specialists have extensive experience in treating patients with advanced heart disease and LVADs.
LVADs are an option for a patient whose heart can no longer pump enough blood to meet the body’s needs. The assistive devices are used in three ways: as a bridge until a transplant donor is found; to stabilize the heart until the muscle might recover; and as a “destination therapy,” i.e. a permanent solution for a person with contraindications to a heart transplant such as kidney disease or advanced age.
NYU Winthrop’s Division of Cardiology is committed to providing the very best, comprehensive care for Long Island residents with cardiovascular disease. The addition of a heart transplantation program to existing specialties enables patients to receive even more comprehensive care close to home. The Hospital also receives accolades as a national leader in Transcatheter Aortic Valve Replacement (TAVR). TAVR is a revolutionary procedure that enables patients with severe aortic stenosis to receive a new heart valve without undergoing open-heart surgery. This minimally invasive technology has been available for high, intermediate and low risk patients with aortic valve stenosis. Most recently, it was approved for patients with no symptoms. Last year, NYU Winthrop was among the top five busiest hospitals in the nation performing this minimally invasive FDA-approved procedure.
Lifesaving Kidney, Liver and Lung Transplants: More Collaboration!
For several decades, specialists at NYU Langone’s Transplant Institute have provided patients with exceptional care, utilizing the latest technological advancements in kidney and liver transplantation, and the Transplant Institute also now offers lung transplants. Fortunately, for NYU Winthrop area residents, pre-surgical evaluations for these types of transplants can be done right at our offices in Mineola. Subsequent transplants are performed at NYU Langone, which offers expertise in transplantation specialties such as:
- Living donor transplantation, in which an organ such as a kidney or portion of the liver is donated by a healthy person.
- Paired kidney transplantation, in which donor and recipient pairs team up to achieve compatible kidneys for each recipient.
- ABO (also known as blood type) and HLA (human leukocyte antigen) incompatible transplantation, where the recipient receives treatment before transplantation so he or she can safely accept an organ from an incompatible donor.
- Ex vivo lung perfusion, a process that allows complete and thorough evaluation of donor lungs otherwise not accepted for transplant by maintaining and assessing the organ outside the body for several hours to enhance the donor lungs’ transplant viability. This may significantly increases the number of lungs available to those on the national waiting list!
At the helm of NYU Langone’s Transplant Institute is Dr. Robert Montgomery, one of the nation’s foremost transplant surgeons, who helped pioneer minimally invasive surgery to remove donor kidneys, novel techniques to reduce the risk of organ rejection, and “domino” kidney transplants, which involve multiple pairs of donors and recipients.
“We’re creating an integrated system between NYU Langone and NYU Winthrop so that a patient in need of therapies for end-stage heart failure encounters a seamless process. We have an exceptionally strong spirit of collaboration, working toward the most successful patient outcomes possible.”
Nader Moazami, MD, Surgical Director of Heart Transplantation and Mechanical Circulatory Support at NYU Langone Health
“We’re bringing the world-class services of NYU Langone’s heart transplant program to our patients locally on Long Island, further elevating our already strong cardiology services. Patients with advanced heart failure often have reduced mobility, so this new collaboration vastly increases patient access. Long Islanders need look no further than their own backyard for the finest in heart care.”
Kevin Marzo, MD, Chief of the Cardiology Division at NYU Winthrop